Pemetrexed plus Gemcitabine

Phase 2Small molecule

MMemorial Sloan Kettering Cancer Center

Pemetrexed plus Gemcitabine is one of 23 small molecule programs targeting Mesothelioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MesotheliomaActive, not recruiting

MesotheliomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Mesothelioma

#DrugCompanyPhaseTrials

Lynparza

Afinitor

Iressa

Nexavar

Zometa

Beleodaq

AAcrotech Biopharma Inc.

Yondelis

Photofrin

PPinnacle Biologics Inc.

Mitosol

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Mesothelioma

NCT00715611

Clinical

Trials by Indication[1]

Recurrent Head and Neck Cancer1 trial

A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00589667·26 enrolled

Mesothelioma1 trial

Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00715611·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pemetrexed plus Gemcitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemetrexed plus Gemcitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemetrexed plus Gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMemorial Sloan Kettering Cancer Center

Pemetrexed plus Gemcitabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Recurrent Head and Neck Cancer1 trial

Mesothelioma1 trial

References

Drug Info

Quick Facts

Related News